Escitalopram and Depression in Elderly Alzheimer's Patients

Phase 3TerminatedNCT00488670

University of British Columbia50 enrolled

Overview

To investigate the effect of Escitalopram in a large and diverse of dementia patients suffering from depression.

This study will assess the efficacy, tolerability, and safety of escitalopram in the treatment of Major Depressive Disorder in patients with Alzheimer's disease over a 24-week period. It will also assess the efficacy and tolerability of escitalopram after 12 weeks of treatment.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Depressive Disorder

Interventions

EscitalopramDRUG

See Detailed Description.

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * \> 50 years * Male \& female * Alzheimer's disease * Depressive episode

Locations (2)

Mt. St. Joseph's Hospital

Vancouver, British Columbia, Canada

Vancouver General Hospital

Vancouver, British Columbia, Canada

Outcomes

Primary Outcomes

Change in Cornell Scale for Depression in Dementia (CSDD) from baseline.

Secondary Outcomes

Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.